Integrating Next-Gen Enteric Coated Capsules: What the Future Holds

Enhancing Targeted Drug Delivery and Regulatory Confidence

Enteric-coated capsules have traditionally played a key role in protecting acid-sensitive drugs from degradation in the stomach. Now, with evolving patient-centric and precision delivery needs, next-gen enteric-coated capsules are being reengineered for greater specificity, controlled release, and regulatory robustness.

Why They Matter

  • Protect APIs from acidic degradation (e.g., enzymes, peptides)
  • Enable targeted delivery to small intestine or colon
  • Reduce GI side effects from irritant compounds
  • Support timed or sustained release applications

Technical Enhancements in Next-Gen Capsules

  • Polymer innovations like HPMCAS, Eudragit, and cellulose derivatives
  • Multi-particulate fills for customized release profiles
  • Dual-coating systems for pH-triggered and time-based performance
  • Compatibility with DPI (dry powder inhaler) encapsulation and depot systems

GMP and Validation Considerations

  • Coating uniformity and disintegration testing per USP/EP
  • Real-time stability testing under ICH conditions
  • Equipment validation for pan coating or fluid bed processes
  • Part 11-compliant documentation and automated inspection systems

Applications

  • Delayed-release NSAIDs, PPIs, or biologics
  • Colon-targeted delivery for IBD, Crohn’s disease
  • Combination products with sequential release needs

With growing demand for personalized dosing and lower GI side effects, next-gen enteric-coated capsules are helping shape the future of targeted, compliant oral therapeutics.

Editorial Team
Author: Editorial Team

Leave a Reply

Your email address will not be published. Required fields are marked *

Total
0
Share
Optimized with PageSpeed Ninja